---
title: Blood tests predict dementia progression
nct_id: NCT06529744
status: RECRUITING
sponsor: University Health Network, Toronto
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06529744"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06529744"
last_fetched: "2026-05-10T14:03:35.316Z"
source: "Parkinson's Pathways (curated)"
---
# Blood tests predict dementia progression

**Goal (in five words):** Blood tests predict dementia progression

**Official Title:** Improving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative Modeling

**Trial ID:** [NCT06529744](https://clinicaltrials.gov/study/NCT06529744)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** University Health Network, Toronto
- **Target Enrollment:** 500 participants
- **Start Date:** 2023-11-11
- **Completion Date:** 2026-11
- **Conditions:** Dementia, Alzheimer Disease, Dementia With Lewy Bodies, Vascular Dementia, Frontotemporal Dementia, Mild Cognitive Impairment, Corticobasal Syndrome, Progressive Supranuclear Palsy, Parkinson Disease, Primary Progressive Aphasia

## Summary For Families

The goal is to improve how confidently clinicians can predict the course of Parkinson's and other neurodegenerative diseases that cause cognitive decline, so patients and families get clearer forecasts about progression and care needs. The approach is observational, gathering peripheral biomarkers like blood tests and other non-brain samples plus detailed clinical and cognitive assessments, then using integrative computational models to combine those signals and produce more accurate, individualized prognoses; it does not change your medical treatment. Adults 30 to 95 with possible or probable mild cognitive impairment or early dementia, who can consent, complete most study procedures, and have a study partner who sees them weekly are being sought.

## Eligibility

- **Minimum age:** 30 Years
- **Maximum age:** 95 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Possible or probable diagnosis of MCI or early dementia
* Age 30-95
* Study partner who has some weekly contact with patient. Some of the neuropsychological assessment require collateral from close contacts to assess cognition and functioning. Since neurodegenerative diseases can be associated with reduced cognition, including reduced awareness of one's own impairments, participants will be assessed for their capacity to consent at all study visits.
* Must, in the opinion of the site investigator, be able to complete most study procedures.

Exclusion Criteria:

* Participants who are not able to complete the majority of assessments in the opinion of the PI are excluded from the study. Exclusion criteria are evaluated at the site investigator's discretion; if the site investigator believes that the participant's symptoms are due to causes other than neurodegeneration, despite the presence of an exclusionary condition, the investigator may overrule the exclusion.
```

## Locations (4)

- Baycrest, North York, Ontario, Canada
  - Aymin Mumtaz — (CONTACT) — 416-785-2500 — amumtaz@research.baycrest.org
  - Morris Freedman, MD — (SUB_INVESTIGATOR)
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada _(43.7064, -79.3986)_
  - Ljubica Zotovic — (CONTACT) — 416-480-6100 — ljubica.zotovic@sunnybrook.ca
  - Sandra E Black, MD — (SUB_INVESTIGATOR)
- Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada _(43.7064, -79.3986)_
  - Claudia Clementi — (CONTACT) — 416-603-5914 — claudia.clementi@uhn.ca
  - Maria C Tartaglia, MD — (PRINCIPAL_INVESTIGATOR)
- Centre for Addiction and Mental Health, Toronto, Ontario, Canada _(43.7064, -79.3986)_
  - Loreque Fearon, BASc — (CONTACT) — 416-535-8501 — Loreque.Fearon@camh.ca
  - Tarek Rajji, MD — (SUB_INVESTIGATOR)
  - Sanjeev Kumar, MD — (SUB_INVESTIGATOR)

## Central Contacts

- Claudia Clementi, HBSc — (CONTACT) — 416-603-5914 — claudia.clementi@uhn.ca

---

*Canonical: https://parkinsonspathways.com/trial/NCT06529744*  
*HTML version: https://parkinsonspathways.com/trial/NCT06529744*  
*Source data: https://clinicaltrials.gov/study/NCT06529744*